Inhaled corticosteroids offer substantial benefit in controlling symptoms for the vast majority of children with asthma. However, poor adherence to therapy is very common, especially among older children and adolescents as they transition to self-management of their disease. The introduction of once-daily inhaled fluticasone furoate, either alone or in combination with the long-acting β-agonist, vilanterol, simplifies chronic asthma therapy and may improve adherence and as a result, outcomes in this vulnerable population. Opportunities exist for additional study of this agent in younger children, particularly with regard to safety and growth suppression. This review provides an overview of the pharmacology, safety and efficacy data regarding use of fluticasone furoate in the treatment of childhood asthma.